Monday, August 31, 2026

Cross Country Healthcare And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Cross Country Healthcare  And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Horizon Therapeutics Public Limited Company (HZNP), Cross Country Healthcare (CCRN), Plains Group Holdings, L.P. (PAGP) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Horizon Therapeutics Public Limited Company (HZNP)

72.5% sales growth and 9.27% return on equity

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally.

Horizon Therapeutics Public Limited Company's sales growth this year is anticipated to be 27.7% and 25.8% for next year.

Year-on-year quarterly revenue growth declined by 3.8%, now sitting on 2.19B for the twelve trailing months.

Volume

Today's last reported volume for Horizon Therapeutics Public Limited Company is 1302020 which is 18.54% below its average volume of 1598380.

Horizon Therapeutics Public Limited Company's sales growth for the next quarter is 72.5%. The company's growth estimates for the current quarter and the next is 120% and negative -16.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.27%.

Volatility

Horizon Therapeutics Public Limited Company's last day, last week, and last month's current volatility was 0.93%, 1.59%, and 1.41%, respectively.

Horizon Therapeutics Public Limited Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.68% (day), 2.80% (last week), and 3.34% (last month), respectively.

Horizon Therapeutics Public Limited Company's Stock Yearly Top and Bottom Value

Horizon Therapeutics Public Limited Company's stock is valued at $93.64 at 17:22 EST, under its 52-week high of $98.33 and way above its 52-week low of $54.27.

Horizon Therapeutics Public Limited Company's Moving Average

Horizon Therapeutics Public Limited Company's worth is above its 50-day moving average of $92.32 and above its 200-day moving average of $86.62.

2. Cross Country Healthcare (CCRN)

45.1% sales growth and 5.42% return on equity

Cross Country Healthcare, Inc. provides talent management and other consultative services for healthcare clients in the United States.

Cross Country Healthcare's sales growth this year is expected to be 34.9% and a negative 17% for next year.

Year-on-year quarterly revenue growth grew by 56.7%, now sitting on 955.59M for the twelve trailing months.

Volume

Today's last reported volume for Cross Country Healthcare is 39527 which is 86.77% below its average volume of 298848.

Cross Country Healthcare's sales growth for the next quarter is 45.1%. The company's growth estimates for the present quarter and the next is 150% and 83.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.42%.

Volatility

Cross Country Healthcare's last day, last week, and last month's current volatility was 0.51%, 1.46%, and 2.74%, respectively.

Cross Country Healthcare's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.26% (day), 3.39% (last week), and 5.32% (last month), respectively.

Cross Country Healthcare's Stock Yearly Top and Bottom Value

Cross Country Healthcare's stock is valued at $16.45 at 17:22 EST, way below its 52-week high of $18.90 and way above its 52-week low of $5.62.

Cross Country Healthcare's Moving Average

Cross Country Healthcare's worth is below its 50-day moving average of $16.60 and way higher than its 200-day moving average of $12.58.

3. Plains Group Holdings, L.P. (PAGP)

23.4% sales growth and 5.66% return on equity

Plains GP Holdings, L.P. owns and operates midstream energy infrastructure in the United States and Canada.

Plains Group Holdings, L.P.'s sales growth this year is anticipated to be 19.4% and a negative 1.1% for next year.

Year-on-year quarterly revenue growth grew by 1.4%, now sitting on 23.4B for the twelve trailing months.

Volume

Today's last reported volume for Plains Group Holdings, L.P. is 1433960 which is 44.24% below its average volume of 2571790.

Plains Group Holdings, L.P.'s sales growth for the next quarter is 23.4%. The company's growth estimates for the current quarter and the next is 144.4% and 155.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.66%.

Volatility

Plains Group Holdings, L.P.'s last day, last week, and last month's current volatility was 0.37%, 1.08%, and 1.59%, respectively.

Plains Group Holdings, L.P.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.50% (day), 2.44% (last week), and 3.39% (last month), respectively.

Plains Group Holdings, L.P.'s Stock Yearly Top and Bottom Value

Plains Group Holdings, L.P.'s stock is valued at $11.62 at 17:22 EST, way below its 52-week high of $12.96 and way higher than its 52-week low of $5.46.

Plains Group Holdings, L.P.'s Moving Average

Plains Group Holdings, L.P.'s value is higher than its 50-day moving average of $11.48 and way higher than its 200-day moving average of $9.87.

4. WD-40 Company (WDFC)

7.4% sales growth and 44.71% return on equity

WD-40 Company develops and sells maintenance products, and homecare and cleaning products in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific.

WD-40 Company's sales growth this year is expected to be 13.1% and 5.7% for next year.

Year-on-year quarterly revenue growth grew by 11.9%, now sitting on 446.36M for the twelve trailing months.

Volume

Today's last reported volume for WD-40 Company is 44907 which is 55.15% below its average volume of 100136.

WD-40 Company's sales growth is a negative 0% for the current quarter and 7.4% for the next. The company's growth estimates for the ongoing quarter and the next is 8.5% and negative -12.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 44.71%.

Volatility

WD-40 Company's last day, last week, and last month's current volatility was 2.19%, 1.26%, and 1.25%, respectively.

WD-40 Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.64% (day), 2.43% (last week), and 2.35% (last month), respectively.

WD-40 Company's Stock Yearly Top and Bottom Value

WD-40 Company's stock is valued at $257.11 at 17:22 EST, way under its 52-week high of $333.42 and way higher than its 52-week low of $183.55.

WD-40 Company's Moving Average

WD-40 Company's worth is higher than its 50-day moving average of $249.51 and under its 200-day moving average of $277.71.

5. Mid Penn Bancorp (MPB)

5.7% sales growth and 12.59% return on equity

Mid Penn Bancorp, Inc. operates as the bank holding company for Mid Penn Bank that provides commercial banking services to individuals, partnerships, non-profit organizations, and corporations.

Mid Penn Bancorp's sales growth this year is anticipated to be 11.6% and a negative 2.3% for next year.

Year-on-year quarterly revenue growth grew by 44.8%, now sitting on 110.9M for the twelve trailing months.

Volume

Today's last reported volume for Mid Penn Bancorp is 85644 which is 40.45% above its average volume of 60980.

Mid Penn Bancorp's sales growth for the next quarter is 5.7%. The company's growth estimates for the ongoing quarter and the next is a negative 21% and negative -15.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.59%.

Volatility

Mid Penn Bancorp's last day, last week, and last month's current volatility was 0.47%, 0.44%, and 1.39%, respectively.

Mid Penn Bancorp's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.41% (day), 2.10% (last week), and 3.09% (last month), respectively.

Mid Penn Bancorp's Stock Yearly Top and Bottom Value

Mid Penn Bancorp's stock is valued at $27.45 at 17:22 EST, under its 52-week high of $29.87 and way above its 52-week low of $17.15.

Mid Penn Bancorp's Moving Average

Mid Penn Bancorp's worth is below its 50-day moving average of $28.16 and above its 200-day moving average of $25.79.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com